Moderna, Inc. (NASDAQ: MRNA) is a Healthcare company (Biotechnology) with a market capitalization of $87.1B. The Maz Rating grades it against the other companies in its sector.
Moderna, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $215.27, Moderna, Inc. trades at 34.5x sales and 12.6x book value. Over the last twelve months it generated about $2.5B of revenue and a net loss of $2.9B. It runs a gross margin of 28.0%, an operating margin of -116.0% and a net margin of -110.5%. It shows return on equity of -37.6%, return on invested capital of -25.6% and a free cash flow yield of -2.3%. On the balance sheet: a debt-to-equity ratio of 0.61 and a current ratio of 3.62. Over the past 52 weeks the share price ranged from $22.28 to $280.80, with a beta of 0.90.
Moderna, Inc. does not currently pay a dividend.
29 Wall Street analyst ratings cover the stock: 7 Buy, 16 Hold and 6 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Moderna, Inc. (MRNA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.76% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.7% / 30% · Interest income / Revenue 4.72% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 4.76% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.94% / 33% · Receivables / Mkt Cap (36m) 1.83% / 49% · Interest income / Revenue 4.72% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 4.76% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.94% / 33.33% · Receivables / Mkt Cap (24m) 1.83% / 33.33% · Interest income / Revenue 4.72% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 11.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 44.2% / 33.33% · Receivables / Avg Assets (4Q) 3.94% / 33.33% · Interest income / Revenue 4.72% / 5% | Fail |
| FTSE | Debt / Total Assets 26.4% / 33.33% · (Cash+ST Inv) / Total Assets 38.4% / 33.33% · (Cash+Recv) / Total Assets 48.5% / 33.33% · Interest income / Revenue 4.72% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Moderna, Inc. (MRNA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Moderna, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 4.72% of each dividend: Moderna, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.